You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥預計將於明年一季度在中國推出新冠治療藥
uSMART盈立智投 12-28 10:51

據《南華早報》報道,騰盛博藥的首席執行官在接受採訪時表示,公司計劃於2022年第一季度在中國推出新冠治療藥物,正在與藥明生物等合作夥伴就其新冠藥物的生產展開討論,預計明年將開始產生收入。美國食品藥品監督管理局(FDA)可能於明年1月批準騰盛博藥的藥品。

12月9日,騰盛博藥在港交所公告稱,國家藥監局已批準公司的單克隆中和抗體安巴韋單抗 ╱ 羅米司韋單抗的聯合療法上市申請,用於治療輕型和普通型且伴有進展爲重型(包括住院或死亡)高風險因素的成人和青少年(12-17歲,體重≥40kg)新型冠狀病毒感染患者。這是我國首家獲批的自主知識產權新冠病毒中和抗體聯合治療藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account